This is a mechanism module, not a specific disease. Disorder entries reference individual nodes via conforms_to (e.g. "epigenetic_machinery_neurodevelopmental_dysregulation#Dysregulated Neurodevelopmental Transcriptional Program").
NOT an Xogenesis module: the terminal output is failure of a normal developmental process, not formation of a pathological anatomical entity, so no OGMS/MPATH anchor stanza applies.
Scope and the four functional classes. The epigenetic machinery comprises three enzymatic classes - writers (KMT2D, KMT2A, EHMT1, NSD1, EZH2, SETD5, CREBBP, EP300, KAT6A, KAT6B), erasers (KDM6A, KDM5C, HDAC8), and chromatin remodelers (the BAF/SWI-SNF subunits ARID1A, ARID1B, SMARCA2, SMARCA4, SMARCB1; CHD7, CHD8) - plus one non-enzymatic class, readers (BRPF1, BRD4, PHF6, ATRX). Enzymatic activities never coexist within a single component, but an individual enzymatic activity often coexists with a reader domain (PMID:31595951). A conforming entry should say which class its component belongs to.
What does NOT conform. This module is about the machinery that maintains chromatin state, not about every transcriptional lesion. A sequence-specific transcription factor whose loss dysregulates its own target genes (FOXP1, SOX11, TBR1) is a transcription-factor disorder, not an MDEM, and should not declare conformance here on that basis alone; nor should the age-associated, partly stochastic epigenetic drift covered by the separate `epigenetic_alterations` aging-hallmark module, which is a different explanandum (drift with age vs. a germline lesion in a machinery component). Cancer-associated somatic mutation of the same genes (SMARCB1 in rhabdoid tumor, EZH2 in lymphoma, SETD2 in renal cell carcinoma) belongs to the cancer hallmark modules, not here.
Deliberately not asserted. The module does NOT claim that global DNA-methylation episignatures are causal. They are robust, clinically deployed diagnostic classifiers and evidence that these disorders share a downstream chromatin consequence, but a peripheral-blood methylation signature is a biomarker of the lesion, not a demonstrated step in the brain's causal chain - this is recorded as an open KNOWLEDGE_GAP discussion rather than curated as a pathophysiology node.
Drug-target pattern. Chromatin-directed therapy (the HDAC inhibitor arm) uses target_mechanisms with INHIBITS on the "Permissive-Repressive Chromatin State Imbalance" node. The rationale is the postnatal malleability of this group: in the Kmt2d(+/betaGeo) Kabuki mouse, postnatal AR-42 treatment normalised H3K4me3 deficiency, dentate-gyrus neurogenesis, and hippocampal memory (PMID:25273096). This is an investigational, mouse-derived pattern and is NOT inherited as a treatment recommendation by conforming disorders; the human-translation gap is recorded as a HUMAN_MODEL_MISMATCH discussion.
Conformers (20 entries, 58 edges) span all four functional classes. WRITERS: Kabuki_Syndrome (KMT2D/KDM6A writer-eraser pair), Rubinstein-Taybi_Syndrome (CREBBP/EP300 acetyltransferase), Kleefstra_Syndrome (EHMT1 H3K9), Weaver_Syndrome (EZH2/PRC2 H3K27), Wiedemann-Steiner_Syndrome (KMT2A H3K4), SETD5_Haploinsufficiency_Syndrome and Luscan-Lumish_Syndrome (SETD2, H3K36), Arboleda-Tham_Syndrome (KAT6A acetyltransferase). ERASERS: Beck-Fahrner_Syndrome (TET3 - the DNA-methylation arm rather than a histone mark), KDM6B-Related_Neurodevelopmental_Disorder (H3K27 demethylase), KDM1A-Related_Neurodevelopmental_Disorder (LSD1). REMODELERS: Coffin_Siris_Syndrome and Nicolaides-Baraitser_Syndrome (BAF; the two share an epi-signature, PMID:30459321), CHD8-Related_Neurodevelopmental_Disorder_with_Overgrowth, CHD2-Related_Developmental_and_Epileptic_Encephalopathy, ATRX_Syndrome. READERS / SCAFFOLDS: BRPF1-Related_Intellectual_Disability (KAT6A/KAT6B scaffold), Borjeson-Forssman-Lehmann_syndrome (PHF6), Bainbridge-Ropers_Syndrome (ASXL3/PR-DUB). COHESIN AND REGULATORS: Cornelia_de_Lange_Syndrome (NIPBL) - attached only at the transcriptional node, because cohesin acts on TAD and loop architecture rather than on permissive-repressive mark balance.
A useful negative control already in the KB: Bainbridge-Ropers_Syndrome carries a node recording the *absence* of an ASXL3 DNA-methylation episignature. That is consistent with, and strengthens, this module's standing KNOWLEDGE_GAP: an episignature is a per-gene diagnostic property, not a necessary feature of belonging to this mechanism class.
Key conformance target: the central_effector "Dysregulated Neurodevelopmental Transcriptional Program" - the disorder-agnostic, rate-limiting step every conformer funnels through regardless of which machinery class is lesioned.
Key-target coverage, stated honestly. Of the 20 conforming entries, 14 declare that node and 6 do not: ATRX_Syndrome, Coffin_Siris_Syndrome, Kabuki_Syndrome, Rubinstein-Taybi_Syndrome, SETD5_Haploinsufficiency_Syndrome and Weaver_Syndrome. This is not an oversight to be tidied away by adding edges. Two distinct causes, both worth preserving:
(1) The entry has no separate transcriptional node because one of its nodes bundles the lesion, the chromatin change and the transcriptional consequence into a single claim (Coffin_Siris_Syndrome, Kabuki_Syndrome). Because conforms_to is single-valued, a bundled node must be attached at whichever module node is its *primary* claim, and the rest of the correspondence is lost. Splitting such a node into atomic ones is the real fix, and is a curation task on that entry rather than something this module can assert.
(2) The entry's transcriptional evidence points somewhere other than neurodevelopment, so declaring this node would overstate it. Weaver_Syndrome is the worked case: its "Impaired Polycomb Repression and Gene Derepression" node is evidenced in an isogenic stem-cell system on genes regulating growth, bridges to overgrowth rather than to brain, and explicitly says the tissue-specific developmental intermediates remain undefined. ATRX_Syndrome is the same shape - its transcriptional node is the G-rich tandem-repeat and alpha-globin arm, which is the haematological mechanism, not the neurodevelopmental one. Both were deliberately left attached at the trigger and chromatin-state nodes only.
Does postnatal HDAC-inhibitor rescue of neurogenesis and memory in the Kmt2d(+/betaGeo) Kabuki mouse predict cognitive benefit in humans with a Mendelian disorder of the epigenetic machinery?
HUMAN MODEL MISMATCH
hdac_rescue_human_translation
Attached to:
Permissive-Repressive Chromatin State Imbalance
The entire chromatin-directed therapeutic rationale for this module rests on a single mouse model of a single MDEM. The mismatch is not that the mechanism is implausible in humans - the chromatin imbalance is well evidenced on both sides - but that three translational steps are untested. First, the mouse readout is postnatal dentate-gyrus neurogenesis and hippocampal memory, which is a far narrower phenotype than human intellectual disability. Second, the human deficit accumulates across a developmental window that has largely closed by the time of diagnosis, so it is unknown how much of the phenotype remains malleable postnatally in humans even if the mouse deficit is. Third, HDAC inhibitors act genome-wide rather than at the affected component's target loci, so the therapeutic index in a developing human brain is unestablished. The review that frames this group as potentially treatable is explicit that the postnatal-treatability observation is recent and its clinical translation prospective, not demonstrated.
Proposed experiments:
Cross-MDEM replication of postnatal chromatin-directed rescue
Human biomarker-anchored early-phase trial
Are the peripheral-blood DNA-methylation episignatures of the chromatinopathies a step in the causal chain to intellectual disability, or a downstream biomarker of the machinery lesion?
KNOWLEDGE GAP
episignature_causal_versus_biomarker
Attached to:
Dysregulated Neurodevelopmental Transcriptional Program
Episignatures are robust enough to reclassify variants of unknown significance and to identify undiagnosed individuals by population screening, and their cross-syndrome similarity - the BAFopathy signature is shared between Coffin-Siris and Nicolaides-Baraitser, sometimes more closely across the two syndromes than within one - is strong evidence that these disorders converge on a common chromatin consequence. But they are measured in peripheral blood, not brain, and no study establishes that the methylation changes themselves mediate the neurodevelopmental phenotype rather than marking the lesion that does. The module therefore treats them as diagnostic and classificatory evidence for convergence at this node, and deliberately does not curate a methylation node in the causal chain.
Proposed experiments:
Brain-versus-blood episignature concordance
Epigenetic Machinery Component Haploinsufficiency
trigger
A dosage-sensitive component of the epigenetic apparatus - a writer, eraser, reader, or chromatin remodeler - is functionally lost. Haploinsufficiency is the predominant disease mechanism for this gene group: a single functional allele is insufficient, so most MDEMs are dominant and caused by truncating or loss-of-function missense variants rather than gain of a new activity. Conforming disorder nodes substitute the specific component and its enzymatic or reader class.
The node name says haploinsufficiency because that is the predominant route, but the claim it makes is reduced functional dosage of the component. A hypomorphic or hemizygous reduced-function allele therefore conforms here too - ATRX_Syndrome is the worked case, where X-linked alleles are typically hypomorphic rather than null. What does NOT conform at this node is a dominant-negative or gain-of-function lesion, where the mutant product actively poisons or redirects the complex rather than simply being absent: those entries should attach further downstream, at the chromatin-state or transcriptional node. Nicolaides-Baraitser_Syndrome (non-truncating SMARCA2 variants acting dominant-negatively on BAF ATPase activity) is curated that way for exactly this reason.
Used by disorders
Kabuki Syndrome
as Chromatin dysregulation from KMT2D and KDM6A haploinsufficiency
Downstream
-
Permissive-Repressive Chromatin State Imbalance
Permissive-Repressive Chromatin State Imbalance
amplifier
Loss of the component shifts the balance between permissive (open, transcriptionally competent) and repressive (closed) chromatin at the loci that component normally acts on. Because writers and erasers of opposing marks act antagonistically on the same nucleosomes, losing one arm is equivalent to unopposed activity of the other: KMT2D haploinsufficiency reduces H3K4 trimethylation and histone acetylation, leaving chromatin inappropriately closed. This imbalance - not the absence of any single mark - is the pathogenic state, and it is what chromatin-directed therapy targets.
Downstream
-
Dysregulated Neurodevelopmental Transcriptional Program
Dysregulated Neurodevelopmental Transcriptional Program
central effector
The rate-limiting, disorder-agnostic step. Altered chromatin state at the component's target loci dysregulates expression of the developmental gene programs those loci encode. This is where the four functional classes converge: whichever component is lost, and whichever mark is perturbed, the shared consequence is that neurodevelopmental transcription is no longer correctly patterned. It is the level at which the chromatinopathies are recognised as one class, and the level at which their clinical overlap - developmental delay, intellectual disability, facial dysmorphism, behavioural disturbance - is explained.
Downstream
-
Impaired Neuronal Maturation, Plasticity, and Postnatal Neurogenesis
Impaired Neuronal Maturation, Plasticity, and Postnatal Neurogenesis
effector
The dysregulated transcriptional program is read out in neurons as failure of the activity-dependent processes that build and tune circuits: dendritic spine formation and actin dynamics, synapse number, long-term synaptic plasticity, and - importantly for this module's therapeutic logic - ongoing neurogenesis in the postnatal dentate gyrus. Because several of these processes continue after birth, the deficit at this node is not purely a fixed developmental endpoint, which is the mechanistic basis for postnatal malleability.
Downstream
-
Intellectual Disability with Growth and Craniofacial Dysmorphism
Intellectual Disability with Growth and Craniofacial Dysmorphism
consequence
The clinical output of the chain, and the reason this group is curated as one class: intellectual disability and developmental delay, accompanied by growth disruption (short stature in Kabuki and Cornelia de Lange, overgrowth in Sotos and Weaver - the direction differs but the dysregulation does not) and a recognisable facial gestalt, often with behavioural disturbance. MDEMs are individually rare but collectively a common aetiology for intellectual disability, which is what makes the shared mechanism worth modelling.